February 7, 2025 – Talk Bio

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

3 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment

Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial

3 months ago talkbio0Tagged Approved, Clinical Trials, eGenesis, Family suidae, Gene-Edited, Kidney, Kidney Failure, Chronic, Organ Shortage, United States Food and Drug Administration, United Therapeutics, Xenograft procedure

xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

3 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude

3 months ago talkbio0Tagged Apretude, HIV Prevention, Lenacapavir, long-acting injectables, PREP gene, SmithKline Beecham, ViiV Healthcare

HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare

Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer

3 months ago talkbio0Tagged cell renal cell carcinoma, Conventional (Clear Cell) Renal Cell Carcinoma, Immunotherapy, Malignant neoplasm of kidney, Neoantigen, personalized cancer, phase 1 trial

personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial